Document ID: FDA-2015-N-3326-0013
Agency: fda
Document Type: Notice
Title: Biosimilar User Fee Act; Public Meeting; Correction
Posted Date: 2016-09-29T04:00Z

[Federal Register Volume 81, Number 189 (Thursday, September 29, 2016)]
[Notices]
[Page 66970]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23523]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2015-N-3326]

Biosimilar User Fee Act; Public Meeting; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Biosimilar User Fee Act; Public Meeting'' that appeared in 
the Federal Register of September 19, 2016 (81 FR 64171). The document 
announced a public meeting to discuss proposed recommendations for the 
reauthorization of the Biosimilar User Fee Act (BsUFA) for fiscal years 
(FYs) 2018 through 2022. The document was published with the incorrect 
date of the closure of the docket and incorrect transcript information. 
This document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Food and Drug 
Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 3330, Silver 
Spring, MD 20993-0002, 301-796-9115, lisa.granger@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the Federal Register of Monday, September 
19, 2016, in FR Doc. 2016-22442, the following corrections are made:
    1. On page 64172, in the first column, in the third sentence of the 
DATES section, ``October 19, 2016'' is corrected to read ``October 28, 
2016.''
    2. On page 64175, in the third column, the section ``Transcripts: 
As soon as a transcript is available, FDA will post it at http://www.fda.gov/ForIndustry/UserFees/BiosimilarUserFeeActBsUFA/ucm461774.htm.'' is corrected to read ``Transcripts: Please be advised 
that as soon as a transcript is available, it will be accessible at 
http://www.regulations.gov and http://www.fda.gov/ForIndustry/UserFees/BiosimilarUserFeeActBsUFA/ucm461774.htm. It may be viewed at the 
Division of Dockets Management, Food and Drug Administration, 5630 
Fishers Lane, Rm. 1061, Rockville, MD. A transcript will also be 
available in either hardcopy or on CD-ROM, after submission of a 
Freedom of Information request. The Freedom of Information office 
address is available on the Agency's Web site at http://www.fda.gov.''

    Dated: September 23, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-23523 Filed 9-28-16; 8:45 am]
BILLING CODE 4164-01-P